Lapatinib Resistance in Patients With Breast Cancer
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
- Genetisk: analyse av genuttrykk
- Annen: laboratoriebiomarkøranalyse
- Genetisk: mutasjonsanalyse
- Genetisk: revers transkriptase-polymerase kjedereaksjon
- Annen: immunhistokjemi farging metode
- Genetisk: polymerase kjedereaksjon
- Legemiddel: lapatinib ditosylat
- Genetisk: fluorescens in situ hybridisering
- Annen: cell sorting
Detaljert beskrivelse
OBJECTIVES:
- To identify secondary ErbB2 mutations in tumor tissue samples from patients with ErbB2-positive breast cancer treated with lapatinib ditosylate.
- To investigate ErbB2 copy number changes and expression levels.
- To determine abnormalities of other pathways (e.g., c-MET and PI3K) as potential mechanisms of resistance.
OUTLINE: Previously collected tumor tissue samples* are obtained for genetic analysis studies. Samples are analyzed for secondary ErbB2 mutations by nested PCR; ErbB2 copy number changes by quantitative PCR and standard histological FISH; and ErbB2 expression levels by quantitative RT-PCR and IHC. Patients also undergo blood sample collection for extraction of DNA (as normal control DNA) and isolation of EpCAM-positive circulating tumor cells using immunomagnetic cell separation technology. Additional research studies may include mutational and amplification analysis of the c-MET and PI3K pathways.
NOTE: *Patients may undergo biopsy if a post-treatment tumor tissue sample is unavailable.
Studietype
Studietype
Kontakter og plasseringer
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
Cleveland, Ohio, Forente stater, 44106-5065
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
-
Cleveland, Ohio, Forente stater, 44024
- Geauga Regional Hospital
-
Cleveland, Ohio, Forente stater, 44060
- Lake/University Ireland Cancer Center
-
Cleveland, Ohio, Forente stater, 44121
- University Suburban Health Center
-
Cleveland, Ohio, Forente stater, 44122
- UHHS Chagrin Highlands Medical Center
-
Cleveland, Ohio, Forente stater, 44130
- Southwest General Health Center
-
Cleveland, Ohio, Forente stater, 44145
- UHHS Westlake Medical Center
-
Cleveland, Ohio, Forente stater, 44708
- Mercy Cancer Center at Mercy Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
DISEASE CHARACTERISTICS:
Pathologically confirmed invasive breast cancer
- ErbB2-positive disease
Has received or is currently receiving lapatinib ditosylate
- Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration OR a radiographic response)
- Must have tumor tissue samples available for research studies
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Not pregnant*
- Coagulation profile normal*
- Platelet count > 100,000/mm³* NOTE: *For patients requiring a post-treatment biopsy
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Concurrent chemotherapy or trastuzumab (Herceptin®) allowed
- No concurrent anticoagulants, including warfarin or low-molecular weight heparin*
- No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents* NOTE: *For patients requiring a post-treatment biopsy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
|---|
|
Secondary ErbB2 mutations
|
|
ErbB2 copy number changes and expression levels
|
|
Abnormalities of other pathways (e.g., c-MET and PI3K) as potential mechanisms of resistance
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Balazs Halmos, MD, Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- CASE15107 (Annen identifikator: Case Comprehensive Cancer Center)
- P30CA043703 (U.S. NIH-stipend/kontrakt)
- CASE-15107-CC488
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .